Overview

Hemodynamic Responses to RLX030 Infusion in Subjects With Acute Heart Failure

Status:
Completed
Trial end date:
2013-01-01
Target enrollment:
Participant gender:
Summary
This study will assess the hemodynamic effect of RLX030 infusion in subjects with acute heart failure. In addition safety and effects on renal function and biomarkers will be assessed.
Phase:
Phase 2
Details
Lead Sponsor:
Novartis Pharmaceuticals